Alnylam Pharmaceuticals
ALNY
216 hedge funds and large institutions have $5.63B invested in Alnylam Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 55 increasing their positions, 86 reducing their positions, and 20 closing their positions.
160% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 20
112% more call options, than puts
Call options by funds: $43.5M | Put options by funds: $20.5M
22% more capital invested
Capital invested by funds: $4.61B → $5.63B (+$1.02B)
16% more funds holding
Funds holding: 186 → 216 (+30)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
36% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 86
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWG
Alpha Wave Global
New York
|
+$127M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$79.5M |
| 3 |
Morgan Stanley
New York
|
+$47.6M |
| 4 |
BRC
Blue Ridge Capital
New York
|
+$39.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$180M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.2M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$39.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.8M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$23.8M |
ALNY Hedge Fund Activity: Q4 2014 in Review
216 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2014, worth a combined $5.63B — up 22% from $4.61B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ALNY positions and 20 closed out — a net gain of 32 holders — while 55 added to existing stakes and 86 trimmed.
The largest buyer was Alpha Wave Global, opening a new position worth an estimated $127M. The largest seller was T. Rowe Price Associates, cutting an estimated $180M.
- 216 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2014, up from 186 in Q3 2014.
- Funds reported $5.63B of Alnylam Pharmaceuticals stock for Q4 2014, up 22% quarter-over-quarter.
- 52 funds opened new Alnylam Pharmaceuticals positions in Q4 2014 and 20 closed out, a net change of +32 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2014 was Alpha Wave Global, an estimated $127M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2014 was T. Rowe Price Associates, an estimated $180M sold.
Based on aggregated 13F filings for Q4 2014.